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Abstract
Background: The cluster randomised crossover (CRXO) design is gaining popularity in trial settings where
individual randomisation or parallel group cluster randomisation is not feasible or practical. Our aim is to stimulate
discussion on the content of a reporting guideline for CRXO trials and to assess the reporting quality of published
CRXO trials.
Methods: We undertook a systematic review of CRXO trials. Searches of MEDLINE, EMBASE, and CINAHL Plus as
well as citation searches of CRXO methodological articles were conducted to December 2014. Reporting quality
was assessed against both modified items from 2010 CONSORT and 2012 cluster trials extension and other
proposed quality measures.
Results: Of the 3425 records identified through database searching, 83 trials met the inclusion criteria. Trials were
infrequently identified as “cluster randomis(z)ed crossover” in title (n = 7, 8%) or abstract (n = 21, 25%), and a
rationale for the design was infrequently provided (n = 20, 24%). Design parameters such as the number of clusters
and number of periods were well reported. Discussion of carryover took place in only 17 trials (20%). Sample size
methods were only reported in 58% (n = 48) of trials. A range of approaches were used to report baseline characteristics.
The analysis method was not adequately reported in 23% (n = 19) of trials. The observed within-cluster within-period
intracluster correlation and within-cluster between-period intracluster correlation for the primary outcome data were not
reported in any trial. The potential for selection, performance, and detection bias could be evaluated in 30%, 81%, and
70% of trials, respectively.
Conclusions: There is a clear need to improve the quality of reporting in CRXO trials. Given the unique features of a
CRXO trial, it is important to develop a CONSORT extension. Consensus amongst trialists on the content of such a
guideline is essential.
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Background
The cluster randomised crossover (CRXO) trial design has
been used to evaluate a range of interventions, in a variety
of settings [1]. In a CRXO trial hospital, schools or other
groups of individuals (“clusters”) are randomly assigned to
a sequence of interventions. Each cluster receives each
intervention at least once in a separate period of time,
leading to the formation of “cluster-periods” [2, 3]. The
design has potentially greater efficiency than a parallel
group cluster randomised trial because the interventions
are compared within each cluster [4].
Every trial design has specific features that need to be
considered in the design, analysis, and reporting stages. In
the case of the CRXO trial, a critical consideration is the
correlation between participants within clusters through
time. Individuals within a cluster tend to have more simi-
lar outcomes than individuals in different clusters. This
similarity is typically measured by the within-cluster
within-period intracluster correlation (ICC). Further-
more, the similarity between two individuals within a
cluster is likely to dissipate as time increases between
the measurement of the two individuals. The similarity
between two individuals within a cluster, but in differ-
ent time periods, is typically measured by the within-
cluster between-period ICC [2–6].
Complete, transparent, and clear reporting of clinical
trials is essential for those using trial reports. Compre-
hensive reporting allows for an assessment of threats to
the validity of the trial results, an assessment of the ad-
equacy of the statistical methods, replication of trial
methodologies, incorporation of the trial’s results in syn-
thesis products such as meta-analyses, and implementa-
tion of the evaluated intervention(s). To assess the
validity of the trial’s results, the methodology should be
reported in enough detail to allow for the evaluation of
selection, performance, and detection biases [7].
The quality of reporting in randomised trials remains
unacceptably low despite the introduction of reporting
guidelines [8, 9]. The CONSORT (Consolidated Standards
of Reporting Trials) statement reporting guideline for par-
allel group randomised trials was developed in an attempt
to improve the quality of reporting of randomised trials.
The CONSORT statement was first published in 1996,
and has since been twice revised, first in 2001 [10] and
then in 2010 [11]. The 2010 CONSORT statement in-
cludes 25 recommended items covering design, conduct,
analysis, and other aspects. Extensions to the parallel
group CONSORT statement have been published for some
alternative designs; however, no extension currently exists
for CRXO trials.
While a CONSORT extension is not available for CRXO
trials, items from the 2012 cluster trials extension [12]
and several items that have been proposed for reporting
stepped wedge trials [13] are directly applicable (e.g.
”Allowance for clustering” and ”Allowance for the number
of steps” in the sample size justification) or are easily
modifiable (e.g. ”Identification as a cluster randomised
trial in title”) for CRXO trials. However, the CRXO design
has distinct characteristics when compared with the paral-
lel group cluster randomised design and the stepped -
wedge design, such as the adverse potential for carryover
of the intervention effect to subsequent periods. There-
fore, a separate reporting guideline for this trial design
may be of value.
Assessing the quality of reporting is the suggested ini-
tial step in developing reporting guidelines [9]. Because
no published reporting guidelines exist for CRXO trials,
in this article we propose possible reporting items, and
indicate areas where items may need to be developed, as
a means to (1) facilitate discussion on possible items that
could be considered for inclusion in a future reporting
guideline, and (2) assess the quality of reporting in
CRXO trials and thus determine if there is a need for a
separate guideline.
To assess the quality of reporting in CRXO trials, we
undertook a systematic review that collected information
on a range of aspects including trialists’ motivations for
using the CRXO design, the design characteristics of
CRXO trials, the statistical methods for sample size and
data, and the quality of reporting of CRXO design aspects.
In a previous publication, we evaluated the appropriate-
ness of the statistical analysis and sample size methods
[1]. In this article we evaluate the quality of reporting in
CRXO trials.
In “Proposed reporting items for CRXO trials” we dis-
cuss potential modifications to the reporting items of the
CONSORT 2012 cluster trials extension for CRXO trials,
and propose areas where items may need to be developed.
In “Systematic review methods” we outline the systematic
review methods. The quality of reporting of CRXO trials
is presented in the “Results” section. We discuss our find-
ings and conclusions in the “Discussion” section.
Proposed reporting items for CRXO trials
In this section we suggest, and provide rationale for, pos-
sible modifications to reporting items of the CONSORT
2012 cluster trials extension for CRXO trials, and
propose areas where items may need to be developed to
address the unique design and analysis characteristics of
CRXO trials. All CONSORT 2012 cluster trials exten-
sion items, proposed modifications, and other indicators
of reporting quality are shown in Table 1.
Title and abstract (Items 1a, b)
The primary reasons for including a description of the
trial design in the title and abstract are to ensure appro-
priate indexing in electronic databases [12, 14] and to
alert the readers to the design so that they are less likely
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Table 1 Quality of reporting of cluster randomised crossover trials as assessed against items from a modified 2012 CONSORT statement extension for cluster randomised trials
and selected items from the 2010 CONSORT statement
Section CONSORT
Item no.
CONSORT 2012 extension for cluster trial
design for Item no.
Reporting quality assessment measure Reported?
(N = 83)
Title and Abstract
Identification of design in title 1a Identification as a cluster randomised trial in the title Identification as a CRXO trial in the title 7 (8%)
Reporting in abstract 1b See Table 2 [14] Identification as a CRXO trial in the abstract 21 (25%)
Background and objectives
Rationale for design 2a Rationale for using a cluster design Rationale for using a cluster design AND a
crossover of interventions at the cluster level
20 (24%)
Hypothesis and objectives 2b Whether objectives pertain to the cluster level, the
individual participant level or both
No modification proposed Not assessed
Trial design
Description of trial design 3a Definition of cluster and description of how the design
features apply to the clusters
Schematic representation of design
(recommended especially for designs with
>2 periods or interventions)
23 (28%)
Definition of the cluster 77 (93%)
Clear differentiation between cluster-period and cluster. Not assessed
Number of clusters 79 (95%)
Number of periods 76 (92%)
Duration of each time period or when the cross over
will occur
Not assessed
Cohort, repeated cross-sectional, or mixture of designs
participants in each period
83 (100%)
Discussion of the potential for carryover to occur 17 (20%)
Reporting of use of washout period 83 (100%)
Participants
Eligibility criteria 4a Eligibility criteria for clusters No modification proposed Not assessed
Interventions
Description of interventions 5 Whether interventions pertain to the cluster level,
the individual participant level or both
No modification proposed Not assessed
Outcomes
Description of outcome measures 6a Whether outcome measures pertain to the cluster level,
the individual participant level or both
No modification proposed Not assessed
Sample size 7a Method of calculation, number of clusters(s) (and whether
equal or unequal cluster sizes are assumed), cluster size, a
coefficient of intracluster correlation (ICC or k), and an
indication of its uncertainty
Was the method for sample size calculation reported, or
justification for no sample size calculation provided?
48 (58%)
Reference to the method used for the sample size calculation Not assessed
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Table 1 Quality of reporting of cluster randomised crossover trials as assessed against items from a modified 2012 CONSORT statement extension for cluster randomised trials
and selected items from the 2010 CONSORT statement (Continued)
Justification for number of clusters 33 (40%)
Justification for number of periods 9 (11%)
Equal or unequal number of periods per cluster Not assessed
Equal or unequal cluster-period sizes 42 (51%)
A value for the within-cluster within-period ICC or variance
components or other measure of correlations within data or
justification for not including
13 (16%)
A value for the within-cluster between-period ICC or variance
components or other measure of correlations within data or
justification for not including
4 (5%)
A reference or explanation for the choice of ICCs or other
measure of correlations
5 (6%)
Reported whether the sample size methodology accounted
for repeated measurements on the same individual
Not assessed
Sequence generation
Method used to generate allocation
sequence
8a Method used to generate the random allocation sequence No modification proposed 36 (43%)
Type of randomisation 8b Details of stratification or matching if used Does the article report whether stratified randomisation used? 83 (100%)
Allocation concealment mechanism
Method used to implement the
allocation sequence
9 Specification that allocation was based on clusters rather than
individuals and whether allocation concealment (if any) was at
the cluster level, the individual participant level, or both
Does the article report whether the people allocating the
intervention sequence to the clusters know the allocation
sequence?
40 (48%)
Does the article report whether people recruiting/identifying
participants knew which intervention sequence has been
assigned to the cluster? (n = 57)a
44 (77%)
Does the article report whether the people recruiting/identifying
participants could have influenced which people were recruited/
identified for inclusion in the study? (n = 57)a
54 (95%)
Implementation
Method used to include clusters
in trial
10a Who generated the random allocation sequence, who enrolled
clusters, and who assigned clusters to interventions
No modification proposed Not assessed
Method used to include individuals
in clusters
10b Mechanism by which individual participants were included in
clusters for the purposes of the trial (such as complete
enumeration, random sampling)
No modification proposed Not assessed
Method of obtaining consent 10c From whom consent was sought (representatives of the cluster,
or individual cluster members, or both), and whether consent
was sought before or after randomisation
From whom was consent sought? 60 (72%)
Was consent sought before or after randomisation of the cluster
when consent was sought from individuals? (n = 30)
16 (53%)
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Table 1 Quality of reporting of cluster randomised crossover trials as assessed against items from a modified 2012 CONSORT statement extension for cluster randomised trials
and selected items from the 2010 CONSORT statement (Continued)
Blinding 11a If done, who was blinded after assignment to interventions
(for example, participants, care providers, those assessing
outcomes) and how.
Were the participants aware of the intervention assigned
to the cluster?
67 (81%)
Were the researchers who delivered the intervention, i.e. caregiver,
aware of the intervention assigned to the cluster?
82 (99%)
If the outcome was self-reported (n = 14), was the participant aware
of the intervention assigned to the cluster?
13 (93%)
If the outcome was assessed by another person (n = 69), was the
outcome assessor aware of the intervention assigned to the cluster?
45 (65%)
Statistical methods 12a How clustering was taken into account Justification for statistical analysis methods Not assessed
Reported whether the analysis was performed at the cluster or
individual level.
78 (94%)
Where there are more than two periods, reported whether a
single correlation is assumed for the within-cluster between-
period correlation
0 (0%)
Was it possible to determine the method for accounting for
both the cluster randomisation and multiple period aspects?
64 (77%)
Was it possible to determine the method for accounting for
the cluster randomisation aspect?
70 (84%)
Was it possible to determine the method for accounting for
the multiple period design aspect?
70 (84%)
Results
Participant flow
Number of clusters and participants 13a For each group, the numbers of clusters that were randomly
assigned, received intended treatment, and were analysed
for the primary outcome
For each group, reported the number of clusters that were
randomly assigned, received intended treatment in each period,
and were analysed for the primary outcome
Not assessed
For each group, reported the number of individuals that were
randomly assigned, received the intended intervention in each
period, and were analysed for the primary outcome
Not assessed
Losses and exclusions 13b For each group, losses and exclusions for both clusters
and individual cluster members
For each group, losses and exclusions for clusters, cluster-periods,
and individual participants
Not assessed
Baseline data 15 Baseline characteristics for the individual and cluster levels
as applicable for each group
Presentation of baseline characteristics data in table
No baseline characteristics table in article 24 (29%)
Reported by total only 8 (10%)
Reported by randomisation sequence with or without total 7 (8%)
Reported by cluster only 2 (2%)
Reported by intervention with or without total 37 (45%)
Reported by cluster and period 2 (2%)
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Table 1 Quality of reporting of cluster randomised crossover trials as assessed against items from a modified 2012 CONSORT statement extension for cluster randomised trials
and selected items from the 2010 CONSORT statement (Continued)
Reported by intervention and period 1 (1%)
Reported by intervention, period, and cluster 2 (2%)
Number analysed 16 For each group, number of clusters included in each analysis For each group, number of clusters, cluster-periods, and
participants included in each analysis, stating reasons for
exclusions
Not assessed
Outcomes and estimation 17a Results at the individual or cluster level as applicable and a
\coefficient of intracluster correlation (ICC or k) for each
primary outcome
A coefficient for the within-cluster within-period correlation
and within-cluster between-period correlation, or other measure
(such as variance components), for each primary outcome
0 (0%)
Generalisability 21 Generalisability to clusters and/or individual participants
(as relevant)
No modification proposed Not assessed
an = 26, no recruitment took place
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to misinterpret the trial results [14]. A proposed modifi-
cation is therefore to identify a trial as a “cluster rando-
mised crossover trial” in title and abstract.
Background and objectives (Item 2a)
Providing a rationale for the trial design in the back-
ground informs the reader why the chosen design is best
suited to address the research question. The cluster ran-
domisation aspect of the CRXO design typically in-
creases the required number of participants when
compared to an individually randomised trial, potentially
exposing more participants to harm than necessary if an
individually randomised design was feasible [12]. In
addition, both the crossover and cluster randomisation
aspects of the CRXO design pose trial design, analysis,
and implementation challenges. Hence, the choice to use
the CRXO design in place of a simpler alternative such
as a parallel group cluster randomised trial or individu-
ally randomised trial requires justification. Therefore, for
a similar reason as proposed in the CONSORT 2012
cluster trials extension [12], we propose that the ration-
ale for the use of cluster randomisation and for the
crossover of interventions at the cluster level is included
in the background.
Trial design (Item 3a)
Reporting the trial design allows the reader to replicate
the design in future trials and assess whether the imple-
mented sample size and analysis methods were appropri-
ate for the design. We suggest that the following items
might be considered important for clearly describing the
design of a CRXO trial. Several of these items have been
adapted from recommendations for reporting stepped-
wedge trials [13]:
 Report the total number of randomised clusters in
the trial.
 Report the total number of planned time periods for
each cluster in the trial.
 Report the duration of each time period, for
example, the duration of time or number of
participants included in each cluster-period before
the intervention is crossed over.
 Report whether the same, different, or a mix of
same and different participants were included in
each cluster-period. These designs are described as
cohort, repeated cross-sectional, or mixture designs,
respectively.
 For complex designs (i.e. designs with more than
two interventions and two periods), consider
including a schematic representation of the trial
design depicting which interventions were allocated
to each cluster in each period. For a simple design,
the participant flow diagram (Item 13) may suffice.
We propose two new items for CRXO trials:
 Report the potential of the effect of the intervention
given in one cluster-period to carry over to subse-
quent cluster-periods.
 Report methods for managing the risk of carryover,
if necessary.
In addition to the above reporting items, we also sug-
gest that articles clearly distinguish between the cluster
and the cluster-period.
Sample size (Item 7a)
Reporting how a sample size calculation has been per-
formed is important for replicability, transparency [12],
and scientific and ethical reasons [15]. Reporting of sam-
ple size elements of cluster randomised trials has been
shown to be incomplete [15]. The sample size calcula-
tion for CRXO trials should account for the predicted
correlations arising from the design [5, 6]. In addition,
the assumed sample size parameters and methodology
should be reported. For CRXO trials, we suggest that the
following sample size items might be considered
important:
 Provide a reference for the sample size methodology
or a description of the method when the method is
not published.
 Report how the sample size methodology accounts
for both the cluster randomisation (e.g. the within-
cluster within-period ICC) and the multiple period
aspects of the design (e.g. the within-cluster
between-period ICC).
 Report how the sample size methodology accounts
for whether the same, different, or a mix of the
same and different participants will be included in
each cluster-period.
 Report the number of clusters, number of periods,
and number of participants per cluster-period, not-
ing which are assumed and which are determined by
the sample size calculation.
 Report whether a variable or constant number of
periods per cluster and participants per cluster-
period is assumed.
 Report the parameter values used to account for
cluster randomisation and multiple periods.
 Provide a justification for the choice of parameter
values and state any constraints on the number of
clusters, number of periods, or number of
participants per cluster-period.
Statistical methods (Item 12a)
The primary reasons for reporting the statistical
methods are to allow for replication and for the reader
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to evaluate whether the methods are appropriate for the
design [11]. For CRXO trials we suggest that the follow-
ing items might be considered:
 Provide a reference for the statistical methodology
or a description of the method when the method is
not published.
 Report whether the analysis was performed at the
individual or cluster level.
 Report how both the cluster randomisation and the
multiple period aspects of the design were
accounted for.
 When there were more than two periods, report
whether a constant within-cluster between-period
ICC was assumed, and, if a constant within-cluster
between-period ICC is not assumed, report what
assumption or methodology was used.
 Describe how missing data will be managed at both
the individual level and the cluster level [16].
Participant flow (Items 13a, b)
The CONSORT 2012 cluster trials extension [12] notes
the importance of providing information on the flow of
clusters through the trial (enrolment, allocation, follow-
up, analysis) in addition to the flow of participants. A
CRXO trial has the added complexity of cluster-periods
nested within each cluster and potentially repeated mea-
surements on some participants within each cluster. An
additional consideration for reporting is the level at
which the analysis is undertaken. The CONSORT 2012
cluster trials extension [12] recommends that if the analysis
is aggregated at the cluster level, it is appropriate to show
only the flow of clusters through the trial, while for analyses
that do not use aggregated data, the flow of individual-level
data should also be presented. However, we consider that it
is important to show the flow of participants even when
the analysis is aggregated at the cluster level, since
aggregate-level analyses depend on the individual-level data.
To facilitate discussion on presenting the flow of the num-
ber of clusters, cluster-period, and participants through a
CRXO, we outline possible modifications to the flow dia-
gram in the CONSORT 2012 cluster trials extension [12]
and present a possible flow diagram in Fig. 1, although the
exact form of the diagram is likely to depend on the trial.
Baseline data (Item 15)
The main reasons for reporting baseline characteristics
are to describe the characteristics of the included popu-
lation and permit an assessment of the success of the
randomisation process. There is additional complexity in
a CRXO design, because participants may be recruited
to clusters over multiple time periods. Two key consid-
erations when reporting participant and cluster charac-
teristics in a CRXO trial are that (1) randomisation only
ensures that, on average, cluster-level characteristics are
balanced at baseline (assuming adequate sequence gen-
eration and allocation concealment), while individual-
level characteristics may be influenced by selection pro-
cesses; and (2) participants are often recruited at mul-
tiple time points, allowing presentation of cluster and
individual characteristics at a single time point or sum-
marised across multiple time points.
The cluster-level and individual-level characteristics
can be either time invariant or time varying. For ex-
ample, in a CRXO trial where hospital wards are rando-
mised, the ward type (e.g. surgical, general medical) will
remain constant for the duration of the trial. However,
other cluster-level characteristics may vary, such as the
type of clinicians working on the ward, due to staff
changes (e.g. medical students and registrars moving in
and out the ward). At the individual level, the character-
istics of the individuals are likely to be time varying
when new individuals are recruited across the periods
(repeated cross-sectional design). However, if the trial is
a cohort design, then individual-level characteristics
such as sex will remain time invariant, while others, such
as weight, may change over the duration of the trial.
We propose that the baseline characteristics are tabu-
lated for each sequence and for each intervention within
each sequence. A possible table for a two-period two-
intervention CRXO trial is shown in Table 2. This table
allows for a number of comparisons to be made for both
time-invariant and time-varying characteristics. To facili-
tate discussion on presenting baseline characteristics in a
CRXO trial, we outline a number potential comparisons,
many of which have been used in published trials (Table 1),
and exemplify these comparisons through Table 2.
Time-invariant characteristics
The time-invariant characteristics are described as follows:
1. Compare time-invariant characteristics of clusters
allocated to sequence AB (Group 1 + Group 2)
with clusters allocated to sequence BA (Group 3 +
Group 4).
2. Compare time-invariant characteristics of partici-
pants recruited to sequence AB (Group 1 + Group 2)
with participants recruited to sequence BA (Group
3 + Group 4) (cohort design).
Comparison 1 allows the success of the randomisation
process to be evaluated. Comparison 2 allows for the
process of recruiting participants into clusters to be eval-
uated. When the number of clusters is small, then
chance imbalances between sequences may occur.
3. Compare time-invariant characteristics of clusters in all
periods allocated to intervention A (Group 1 +Group
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Fig. 1 Possible modifications to the CONSORT 2012 cluster trials extension flow diagram (Item 13) for reporting cluster randomised crossover trials
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4) with clusters allocated to intervention B (Group 2 +
Group 3).
4. Compare time-invariant characteristics of participants
recruited to intervention A (Group 1 +Group 4) with
participants recruited to intervention B (Group 2 +
Group 3) (cohort design).
Comparisons 3 and 4 are equivalent to comparisons 1
and 2 when there is no loss of clusters or participants
over time.
Time-varying characteristics
The time-varying characteristics are described as follows:
5. Compare time-varying characteristics of clusters
allocated to sequence AB (Group 1 + Group 2) with
clusters allocated to sequence BA (Group 3 +Group 4).
6. Compare time-varying characteristics of participants
recruited to sequence AB (Group 1 +Group 2) with
participants recruited to sequence BA (Group 3 +
Group 4) (cohort and repeated cross-sectional design).
Comparisons 5 and 6 are likely to be of limited value.
Presenting cluster-level characteristics summarised over
multiple time periods can obscure whether randomisa-
tion was successful if systematic changes have occurred
within the clusters. Likewise, presenting individual-level
characteristics summarised over multiple time periods
can obscure whether systematic changes have occurred
in the recruitment of participants within the clusters.
7. Compare time-varying characteristics of clusters in
all periods allocated to intervention A (Group 1 +
Group 4) with clusters allocated to intervention B
(Group 2 + Group 3).
8. Compare time-varying characteristics of participants
recruited to intervention A (Group 1 +Group 4) with
participants recruited to intervention B (Group 2 +
Group 3) (cohort and repeated cross-sectional design).
As for comparisons 5 and 6, comparisons 7 and 8 also
summarise cluster-level and individual-level characteris-
tics over multiple time periods.
9. Compare time-varying characteristics of clusters
allocated to intervention A with clusters allocated
to intervention B, in the first period only (Group 1
vs Group 3).
10. Compare time-varying characteristics of participants
recruited to intervention A with participants
recruited to intervention B, in the first period only
(Group 1 vs Group 3) (cohort and repeated
cross-sectional design).
The considerations for comparisons 1 and 2 apply also
to comparisons 9 and 10. However, comparisons 9 and 10
do not allow any evaluation of change in the characteris-
tics over time and do not consider all participant data.
11.Compare characteristics of clusters allocated to
intervention A with clusters allocated to intervention
B, separately for each sequence (Group 1 vs Group 2
AND Group 3 vs Group 4).
12.Compare characteristics of participants recruited to
intervention A with participants recruited to
intervention B, separately for each sequence (Group
Table 2 Possible presentation of baseline characteristics in two-period two-intervention cluster randomised crossover trial
Characteristic Intervention sequence AB Intervention sequence BA
Period 1–Intervention A
Group 1
Period 2–Intervention B
Group 2
Period 1–Intervention B
Group 3
Period 2–Intervention A
Group 4
Time-invariant characteristics
Time-invariant cluster
characteristic
Such as proportion of
each ward type:
Cardiac: 25%
Intensive Care: 40%
Neurology: 35%
Such as proportion of
each ward type:
Cardiac: 25%
Intensive Care: 40%
Neurology: 35%
Such as proportion of
each ward type:
Cardiac: 35%
Intensive Care: 45%
Neurology: 20%
Such as proportion of
each ward type:
Cardiac: 35%
Intensive Care: 45%
Neurology: 20%
Time-invariant participant
characteristic (cohort
design only)
Such as patient sex:
59% male
Such as patient sex:
59% male
Such as patient sex:
48% male
Such as patient sex:
48% male
Time-varying characteristics
Time-varying cluster
characteristic
Nurse-to-patient ratio over
24 h, Median (IQR):
2.1 (2.0 – 2.2)
Nurse-to-patient ratio over
24 h, Median (IQR):
2.0 (1.9 – 2.1)
Nurse-to-patient ratio over
24 h, Median (IQR):
2.3 (2.1 – 2.4)
Nurse-to-patient ratio over
24 h, Median (IQR):
2.2 (2.1 – 2.4)
Time-varying participant
characteristic (cohort and
repeated cross-
sectional design)
Such as patient weight (kg),
Mean (SD):
83.4 (14.2)
Such as patient weight (kg),
Mean (SD):
78.9 (15.6)
Such as patient weight (kg),
Mean (SD):
81.2 (13.2)
Such as patient weight (kg),
Mean (SD):
80.4 (11.2)
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1 vs Group 2 AND Group 3 vs Group 4) (cohort
and repeated cross-sectional design).
13.Compare characteristics of clusters allocated to
intervention A with clusters allocated to intervention
B, separately for each period (Group 1 vs Group 3
AND Group 2 vs Group 4).
14.Compare characteristics of participants recruited to
intervention A with participants recruited to
intervention B, separately for each period (Group 1
vs Group 3 AND Group 2 vs Group 4) (ohort and
repeated cross-sectional design).
Presentation of cluster-level and individual-level char-
acteristics separately by period in each intervention
(comparisons 11–14) allows for assessment for any sys-
tematic change in characteristics over time or any poten-
tial interaction between intervention and time. Such
changes will be obscured by presenting characteristics
summarised over multiple time periods.
Number analysed (Item 16)
Reporting the number of clusters, cluster-periods, and
participants that contribute to each analysis of each out-
come is essential to interpreting the results. To facilitate
discussion on presenting the numbers analysed in CRXO
trials, we outline a potential approach:
 Present the number of clusters, cluster-periods, and
participants analysed for the primary outcome as per
the participant flow diagram (Fig. 1).
In addition, for each secondary analysis and outcome,
either state that the same clusters, cluster-periods, and
individuals are included as in the primary analysis, or
where the number analysed differs from Fig. 1:
 Report the number of clusters that contribute to the
analysis across all periods, also separately by
intervention sequence, and give reasons for the
exclusion of any whole clusters.
 Report the number of clusters that contribute to the
analysis for only some periods, also separately by
intervention and intervention sequence. Give
reasons for the exclusion of any cluster-periods and
state whether the remaining clusters-periods from
that cluster were included.
 Report the number of participants included in the
analysis, by intervention and intervention sequence,
including the reasons for any exclusions at the
individual level.
Outcomes and estimation (Item 17a)
The importance of providing estimates of within-cluster
correlation in cluster randomised trials for the purpose
of describing the clustering and future sample size esti-
mation is well recognised [12]. For similar reasons, in
CRXO trials it is important to provide estimates of
within-cluster between-period ICCs, in addition to the
within-cluster within-period ICCs for each outcome. Al-
ternatively, if mixed models are used, the reporting of
variance components can be provided from which the
ICCs can be calculated.
Methods
The protocol for the review has been published [17].
Here we provide only a brief overview of the methods,
along with deviations from the planned methods, and
outline the measures used to assess reporting quality.
Literature search
In brief, MEDLINE, PubMed, EMBASE, and CINAHL
Plus were searched until December 2014 for English
language articles of CRXO trials. In addition to search-
ing for CRXO trials, we searched PubMed for CRXO
methodology articles to identify further references to
CRXO trials. A citation search of all identified method-
ology articles was performed in Web of Science. Finally,
the references of all eligible articles were screened for
CRXO trials. No restriction was applied to the publication
date. The search strategies for CRXO trials and CRXO
methodology articles are outlined in Arnup et al. [17] and
provided in Additional file 1.
Trial inclusion criteria
Trials that met the following inclusion criteria were in-
cluded in the review: the trial was undertaken in humans;
the allocation of the intervention was to clusters of indi-
viduals rather than individuals themselves; each cluster
received each intervention in a sequence over time (con-
ventional crossover design), or at least some clusters
crossed over from one intervention to another (such as
two-treatment-four-sequence designs AA, AB, BA, and
BB); at least some clusters crossed each way between at
least two interventions (e.g. one cluster received AB and
one cluster received BA and therefore excludes pre-post
designs); and the intervention given in the one period was
not deliberately intended by design to affect individuals in
subsequent periods (e.g. interventions intended to change
the prescribing behaviour of health care providers). The
latter two criteria were added while undertaking the re-
view. Protocols were included in the review; however, for
this article the focus is on the quality of reporting of trial
reports, and hence protocols have been excluded.
Selection of trials for inclusion in the review
One author (SA) assessed all titles and abstracts using
the eligibility criteria, and 50% of the titles and abstracts
were screened independently by at least one co-author.
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All full-text articles were then assessed by one author
(SA) using the eligibility criteria. Of these, all eligible ar-
ticles were double screened, along with 20% of articles
that were initially determined to be ineligible. Differ-
ences in inclusion decisions were resolved by discussion
or by referral to a third author. No ineligible articles
were subsequently found to be eligible.
Data extraction and management
One author (SA) extracted data from all trials, and data
from 20% of the trials were independently double data ex-
tracted by the co-authors. Three of the five authors (SA,
JM, AF) reviewed the discrepancies arising from the
double data extraction and discussed processes for further
reviewing items where there was inconsistency. The pro-
cesses and items where further review was undertaken are
described in Arnup et. al. [17]. The data extraction form
was piloted on five trials by each author. Data were en-
tered into a database (Microsoft Access 2010, Redmond,
Washington, USA).
To examine the reporting quality of the CRXO trials,
we extracted reported information from the trials on se-
lected 2012 cluster trial CONSORT extension items
[12], with modification so that they were suitable to as-
sess CRXO trials (Items 1a,b and Item 2a of the 2012
cluster trials extension [12]; hereafter we only refer to
the item number). Where the CONSORT extension may
not have adequately covered the unique characteristics
of CRXO trials, we extracted information on indicators
of the reporting quality for that item (Item 3a, Item 7a,
Item 8b, Item 9, Item 10c, Item 12a, Item 15, Item 17a).
We refer to these measures as indicators because further
discussion between trialists using the CRXO design is
required to determine if the measure adequately assesses
reporting quality.
We did not extract information on CONSORT items
where the reporting considerations did not differ from a
parallel group cluster trial or individually randomised
trial, e.g. description of the interventions and outcome
measures (Item 2b, Item 3b, Items 4a, b, Item 5, Items
6a, b, Item 7b, Items 10a, b, Item 11b, Item 12b, Items
14a, b, Item 17b, Items 18–25.). However, there were
two exceptions where we did extract information on the
following 2010 CONSORT items [11]: Item 8a “Method
used to generate random allocation sequence” because
the item is required to evaluate the potential for selec-
tion bias, and Item 11a “Who was blinded after assign-
ment to intervention?” because the item was required to
evaluate the risk of detection bias (see the next para-
graph). For Item 13 “Participant flow” and Item 16
“Number analysed”, we present a discussion of possible
reporting approaches only.
In addition to assessing the quality of reporting of
CRXO trials against reporting items and indicators, we
assessed whether the reported information was sufficient
to judge the risk of selection, performance, and detection
bias. The Cochrane Handbook for Systematic Reviews of
Interventions, Section 8.4, defines selection bias as sys-
tematic differences between baseline characteristics of
the groups that are compared; performance bias as
systematic differences between groups in the care that is
provided, or in exposure to factors other than the
interventions of interest; and detection bias as systematic
differences between groups in how outcomes are deter-
mined. (See Higgins JPT, Green S (editors). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 [updated March 2011]. The Cochrane Collaboration,
2011. Available from http://handbook.cochrane.org/.)
The full list of extracted data is available in Arnup et
al. [17]. The extracted data specific to reporting quality
in CRXO trials were: identification of the design in the
title or abstract; justification for using the design;
selected design characteristics including schematic rep-
resentation of the design, definition of the cluster, number
of clusters, number of periods, type of design (cohort, re-
peated cross-sectional, or mixture of designs), and man-
agement of the risk of carryover of intervention effects
between periods; reporting of sample size calculation de-
tails including justification for the number of clusters, jus-
tification for the number of periods, equal or unequal
cluster-period sizes, the assumed measure of similarity
between the outcomes of individuals within a cluster
within a given period and justification for assumption, and
the reported measure of similarity between outcomes of
individuals within a cluster between different periods and
justification for assumption; methods used in the trial
including recruitment, consent, randomisation, allocation,
and blinding; statistical analysis including level of analysis,
the method accounting for the similarity between the out-
comes of individuals within a cluster within a given period
and the similarity between outcomes of individuals within
a cluster between different periods, and the reported
measure of similarity between outcomes of individuals
within a cluster between different periods; losses and
exclusions of participants; and reporting of baseline
characteristics.
Data coding
In the section, we provide details on how we judged
each reporting quality measure.
We classified the following items as reported if a clear
statement addressing the item was provided in the trial
report: Items 1a, b, Item 2a, Item 10c, Item 12a, Item
15, and Item 17a.
For items that were not explicitly reported in the trial
report, we reviewed the reported methods to determine
whether enough information was provided to classify the
following items as reported: same, different, or a mix of
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participants in each period (Item 3a); equal or unequal
cluster sizes in the sample size calculation (Item 7a); use
of restricted randomisation (Item 8b); items addressing
allocation concealment (Item 9); and blinding (Item 11)
methods.
We classified the method of random allocation (Item 8a)
as “reported” if the article included details on how the ran-
dom allocation was achieved or clearly stated that the allo-
cation was not random. The method of random allocation
in articles that stated that the allocation was “at random”,
with no further detail, was classified as “not reported”.
We classified the information reported in each trial as
either sufficient or insufficient to assess the risk of selec-
tion bias, performance bias, and detection bias. To as-
sess whether sufficient information was reported to
judge the risk of selection bias, we required that enough
detail was reported to assess (1) whether the researcher
allocating the cluster to the intervention sequence was
blind to future allocation assignments (Item 9); (2)
whether the people recruiting or identifying participants
knew which intervention sequence had been assigned to
the cluster (Item 9); (3) whether the researcher recruit-
ing or identifying participants could influence which in-
dividuals were included in the trial (Item 9); and if the
individual participant (or other person on their behalf )
provided consent, whether they had knowledge, prior to
consenting, of the intervention assigned to the cluster
(Item 10c). To assess whether sufficient information was
reported to judge the risk of performance bias, we re-
quired that enough detail was reported to assess if either
the participants or those delivering the intervention (e.g.
health care professionals) were aware of the intervention
(Item 11a). To assess whether sufficient information was
reported to judge the risk of detection bias, we required
that enough detail was reported to determine if the
assessment of outcomes was self-reported or measured
by another person and whether the assessor was aware
of the intervention assigned to the cluster (Item 11a).
Data analysis
We present descriptive summary statistics using frequen-
cies and percentages of responses to categorical data. Free
text was classified and frequencies and percentages of the
categories are presented. The extracted data from individ-
ual trials can be made available upon request to the
corresponding author.
Results
Results of the search
Figure 2 shows the flow diagram of the CRXO trial selec-
tion process for the systematic review. Of the 3425
records identified through database searching, 170 were
duplicates and 3046 were ineligible based on screening of
abstracts, leaving 209 full-text articles to assess for
eligibility. Of these 209 articles, 99 were assessed as
eligible. A further four articles were identified through the
methodology article reference and citation search, and
three articles from the references of eligible articles. In this
article we further exclude eight trials where only a proto-
col was available. In total, 98 articles from 83 trials were
included in this paper. Seventy-one trials had only one
associated article, nine trials had two associated articles,
and three trials had three associated articles.
Characteristics of the trials
Most trials were conducted in a developed country (n = 79,
95%) and were undertaken within a single country (n = 80,
96%) (Additional file 2: Table S1). The types of clusters var-
ied, with almost half of the trials (n = 40, 48%) randomising
hospitals or wards within hospitals, 13 (16%) randomising
individual health care providers, and 11 (13%) randomising
schools or classes (Additional file 3: Table S2).
The trials investigated a wide range of diseases and
conditions and health care delivery models. Nineteen
trials (23%) investigated infection control, ten (12%) in-
vestigated cardiovascular disease, nine (11%) examined
the delivery of health services, and eight (10%) investi-
gated infectious diseases (Table 3).
The most common trial design involved two interven-
tions (n = 74, 89%). The majority of trials (70%) used two
periods. Trials had a median of eight clusters (IQR: 3 –
21, range: 2– 268) and a median cluster-period size of
27 (IQR: 14–77, range: 2–1319) (Table 2).
In 42 trials (51%) the interventions were delivered dir-
ectly to the individuals within the clusters. In 21 trials
(25%) the intervention was targeted at the health care
provider rather than the individuals under their care,
and in 14 trials (17%) the intervention was targeted at
the organisation of the health care provider or health
services delivery (Table 2).
Quality of reporting in CRXO trials as assessed against
proposed or modified reporting items and other
indicators
Trials were infrequently identified as “Cluster Randomised
Crossover” trials in the title (8%) or in the abstract (25%).
A rationale for both the cluster randomisation and cross-
over aspects of the design was provided in 20 trials (24%).
Most design characteristics were reported; however, trials
infrequently used a schematic to illustrate the design
(28%), even in designs with either more than two periods
or more than two interventions (30%, n = 7/23) (Table 1).
The reporting of the methods used to generate the al-
location sequence and assign the allocation sequence to
clusters was incomplete in 43% (n = 36) and 48% (n = 40)
of trials, respectively. In 20% (n = 17) of the trials, the
risk of a carryover of the intervention effect from one
period to subsequent periods was discussed (Table 1).
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Reporting of the methods and parameters to calculate
the sample size was often missing or incomplete. Only 48
trials (58%) provided a sample size calculation or justifica-
tion for not performing a sample size calculation. Thirty-
three trials (40%) provided justification for the number of
clusters, and only nine trials (11%) provided justification
for the number of periods. Of the 83 trials, only 13 (16%)
reported the within-cluster within-period ICC, and only
four (5%) reported the within-cluster between-period ICC
(or corresponding variance components) that was as-
sumed in the sample size calculation (Table 1).
The construction of the baseline characteristics tables
of the individual participants varied. In most trials, the
characteristics were reported by intervention group
(45%); some trials reported by intervention sequence
(8%). In 24 trials (29%), no baseline characteristics table
was presented (Table 1).
Most trials gave sufficient detail to determine
whether the analysis was performed at the level of the
individual or the level of the cluster (n = 78, 94%).
However, in 19 trials (23%) it could not be determined
how or whether the analysis accounted for the cluster
randomisation or multiple period aspects of the design.
No trial reported a measure of both intracluster corre-
lations or variance components induced by the cluster
randomisation and multiple period aspects of the
Fig. 2 Flow of articles through the systematic review
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design (Table 1). One trial reported the within-cluster
ICC from an analysis that included only a random
effect for cluster, therefore assuming that the within-
cluster between-period ICC was equal to the within-
cluster within-period ICC.
Quality of reporting in CRXO trials to allow assessment
of bias
Selection bias
Twenty-five trials (30%) provided sufficient information to
assess the risk of selection bias (Table 4). In 43 trials (52%)
we were unable to judge the risk of selection bias because
we could not determine whether the researchers respon-
sible for allocating the intervention sequence to the clus-
ters were aware, or not, of the intervention sequence; in
13 trials (17%) we were unable to judge the risk of selec-
tion bias because it was not clear whether the researchers
recruiting participants were aware, or not, of the cluster’s
intervention sequence; in three trials (4%) we were unable
to judge the risk of selection bias because we could not
judge whether the researchers responsible for recruiting/
identifying participants were able to influence recruitment;
and in 14 of the 30 trials (47%) where individual consent
was sought, we could not assess the risk of selection bias
because we could not judge whether the participant was
aware of the intervention assigned to the cluster prior to
giving consent.
Performance bias
Sixty-seven trials (81%) provided sufficient information
to assess performance bias (Table 4). In the 16 trials
(19%) that did not provide sufficient detail to assess the
risk of performance bias, we could not judge whether
the intervention was concealed, or not, from the partici-
pants. In one trial (1%) we also could not judge whether
the intervention was concealed, or not, at cluster level.
Detection bias
Fifty-eight trials (70%) provided sufficient information to
assess detection bias (Table 4). Of the 14 trials (17%) in
which the primary outcome was self-report, we could
not judge if the participant was aware, or not, of the
intervention assigned to the cluster-period in one trial
(7%). Of the 69 trials (83%) where the primary outcome
was not self-report, we could not judge if the assessor
was aware, or not, of the intervention in 24 trials (35%).
Discussion
We proposed possible reporting items for CRXO trials
as a basis for further discussion and to examine report-
ing quality. The items were either modified from those
Table 3 Characteristics of the cluster randomised crossover trials
Disease or domain under study n (%)
(N = 83)
Infection control 19 (23%)
Cardiovascular disease 10 (12%)
Health services delivery 9 (11%)
Infectious disease 8 (10%)
General and public health 5 (6%)
Medical training 5 (6%)
Communication of health information 4 (5%)
Pregnancy, childbirth, and early childhood 3 (4%)
Mental health and behavioural conditions 3 (4%)
Respiratory disease 3 (4%)
Blood sample contamination 3 (4%)
Cognition 3 (4%)
Central nervous system and musculoskeletal disease 2 (2%)
Oral health 2 (2%)
Nutritional and metabolic disorders 1 (1%)
Urogenital disease 1 (1%)
Digestive disorders 1 (1%)
Pain management 1 (1%)
Type of intervention
Intervention targeting the individual 42 (51%)
Intervention targeting health care provider 21 (25%)
Quality improvement intervention 14 (17%)
Intervention resulting in change to the participant
environment
6 (7%)
Number of interventions
2 74 (89%)
3 8 (10%)
4 1 (1%)
Number of clusters - Median [IQR];
Range
8 [3–21];
2 – 268
Unclear 4 (5%)
Number of periodsa
2 53 (70%)
3 8 (11%)
4+ 15 (18%)
Unclear 7 (8%)
Cluster-period size - Median [IQR];
Range
27 [14–77];
2 – 1319
Unclear 17 (20%)
aPercentages of non-missing data presented
Table 4 Quality of reporting in CRXO trials of material required
to assess selection, performance, and detection biases
Bias Sufficient information to evaluate risk of bias
(N = 83)
Selection bias 25 (30%)
Performance bias 67 (81%)
Detection bias 58 (70%)
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in the 2010 CONSORT [11] and 2012 cluster trial exten-
sion statements [12] or were proposed reporting indica-
tors. Incomplete reporting of the design aspects that are
unique to the CRXO design was found to be common in
the published trials included in the systematic review.
The frequency of reporting of sample size calculations
was similar in CRXO trials compared with other rando-
mised trial designs, including individually randomised tri-
als, parallel group cluster randomised trials, individual
crossover trials, and stepped - wedge trials [8, 15, 18–21].
Reporting of the ICCs assumed in the sample size calcula-
tion was poorer in CRXO trials compared with parallel
group cluster randomised trials, with the within-cluster
within-period ICC and within-cluster between-period ICC
assumed in the sample size calculation only reported in
5% of CRXO trials compared with 35% in parallel group
cluster randomised trials [15]. Furthermore, no CRXO
trial reported both the ICC observed in the analysis and
the ICC assumed in the sample size calculation, compared
with 11% of parallel group cluster randomised trials [15].
The completeness of reporting risk of bias domains
for CRXO trials was better than previously observed
estimates for the domains: method of random sequence
generation, method of allocation concealment, and
blinding [8, 18, 19, 21]. This more complete reporting
may reflect our generous assessment of complete report-
ing for these domains, or the greater number of trials in
this review that were published after the publication of
the 2010 CONSORT statement [11] and 2012 cluster
trials extension [12]. However, these domains were still
incompletely reported in around half of CRXO trials.
Complete reporting of individually randomised cross-
over trials allows identification of the potential for carry-
over and of the methods used to manage potential
carryover, including the use of washout periods. While
we were able to judge if a washout period had been used
in all CRXO trials, discussion of the potential for carry-
over only occurred in 20% of trials included in this
systematic review. This estimate was similar to that ob-
served in a study examining the reporting of individually
randomised crossover trials (29%) [19]. Previous esti-
mates for the reporting of the use of a washout period
include 70% [19] and 99% [20].
Assessing the quality of reporting of published CRXO
trials is a recommended initial step in developing report-
ing guidelines [9]. This should be undertaken in combin-
ation with reviewing relevant existing guidelines to
determine whether it is most appropriate to amend an
existing guideline or develop a new guideline. The
CRXO design has unique features, and reporting guid-
ance for these features is currently not addressed by
items in existing guidelines [11–13]. Therefore, it was
necessary to concurrently propose reporting items and
assess the quality of reporting against these items.
The results of the present study suggest a need for
improved reporting of CRXO trials, and given the lack
of specific guidance for this design, a CONSORT exten-
sion would be of value. Recommended next steps would
include setting up a consensus process, including partici-
pants with relevant expertise, to decide upon the specific
items and their wording [9]. However, in the absence of
specific guidance for this design, our suggested modifica-
tions may usefully inform reporting of CRXO trials until
formal guidelines are developed.
Strengths and limitations
Our review represents the most comprehensive review
of this trial design to date, despite some potential limita-
tions in the methods used to locate CRXO trials, which
have been previously discussed [1]. In brief, it may be
argued that better reported trials are easier to locate,
and thus, our results may present an optimistic view of
the reporting quality in CRXO trials.
Our conclusions of the reporting quality in CRXO tri-
als may also depend on our chosen reporting quality
measures. However, our reporting quality items were
predefined, and were based on items modified from the
2010 CONSORT statement [11] and 2012 cluster trials
extension [12] wherever possible. However, the next step
would be to undertake a more rigorous process to refine
and agree upon the reporting items using a consensus
process such as the Delphi method.
Conclusions
We have proposed possible reporting items for CRXO
trials as a basis for further discussion and to examine
reporting quality. We found that incomplete reporting
of the design aspects that are unique to the CRXO
design was common in the published trials included in
this systematic review. Given these results, it is im-
portant that a CONSORT extension is developed.
Consensus amongst trialists on the content of such a
guideline is essential.
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